BS_CGB2WS2A
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 55.84756898817346
- age_years
- 5.901
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.308
- ADIPOGENESIS+0.306
- MYOGENESIS+0.286
- HEME_METABOLISM+0.270
- NOTCH_SIGNALING+0.267
- KRAS_SIGNALING_DN+0.264
- HEDGEHOG_SIGNALING+0.238
- UV_RESPONSE_DN+0.234
- PANCREAS_BETA_CELLS+0.223
- XENOBIOTIC_METABOLISM+0.202
Top 10 suppressed
- E2F_TARGETS-0.633
- MYC_TARGETS_V1-0.611
- MYC_TARGETS_V2-0.572
- G2M_CHECKPOINT-0.540
- UNFOLDED_PROTEIN_RESPONSE-0.372
- DNA_REPAIR-0.355
- MTORC1_SIGNALING-0.324
- INTERFERON_ALPHA_RESPONSE-0.316
- ALLOGRAFT_REJECTION-0.308
- TNFA_SIGNALING_VIA_NFKB-0.297
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_VMMJYN8Z | Ganglioglioma | — | 0.889 |
| 2 | BS_ET8CJXSF | pilocytic astrocytoma | — | 0.887 |
| 3 | BS_SDA4RMMG | pilocytic astrocytoma | — | 0.870 |
| 4 | BS_CVGFNCBJ | low-grade glioma | — | 0.868 |
| 5 | TCGA-44-6776-01A-11R-1858-07 | — | cohortA2 | 0.855 |
| 6 | SRR1356444 | GTEX | — | 0.855 |
| 7 | TCGA-97-7547-01A-11R-2039-07 | — | cohortA1 | 0.842 |
| 8 | BS_13CGKADW | pilocytic astrocytoma | — | 0.839 |
| 9 | BS_TMTV769C | low-grade glioma | — | 0.834 |
| 10 | SRR8518290 | — | F | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.308 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.306 | Inavolisib | — uncovered |
| MYOGENESIS | 0.286 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.270 | Temsirolimus | — uncovered |
| NOTCH_SIGNALING | 0.267 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.264 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.238 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.234 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.223 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.202 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.164 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.151 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.145 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.106 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.089 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.069 | Remibrutinib | — uncovered |